Glenn Frank Short - 01 Jan 2025 Form 3 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Chief Scientific Officer
Signature
/s/ Ryan Barrett, Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
3
Filing time
10 Jan 2025, 16:15:52 UTC
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATAI Common Shares 22,994 01 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATAI Stock Option 01 Jan 2025 Common Shares 283,280 $2.44 Direct F1
holding ATAI Stock Option 01 Jan 2025 Common Shares 329,552 $5.68 Direct F1
holding ATAI Stock Option 01 Jan 2025 Common Shares 53,680 $11.71 Direct F2
holding ATAI Stock Option 01 Jan 2025 Common Shares 180,000 $5.54 Direct F3
holding ATAI Stock Option 01 Jan 2025 Common Shares 71,620 $2.86 Direct F4
holding ATAI Stock Option 01 Jan 2025 Common Shares 250,000 $1.18 Direct F5
holding ATAI Stock Option 01 Jan 2025 Common Shares 388,000 $1.84 Direct F6
holding ATAI Restricted Stock Unit 01 Jan 2025 Common Shares 32,500 $0.000000 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested.
F2 The stock option vested as to 25% of the underlying shares on April 29, 2022, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
F3 The stock option vested as to 25% of the underlying shares on January 1, 2023, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
F4 The stock option vested as to 25% of the underlying shares on September 1, 2023, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
F5 The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
F6 The stock option vested as to 25% of the underlying shares on January 1, 2025, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
F7 Each restricted stock unit represents a contingent right to receive one common share of the Company upon vesting and settlement. The restricted stock units will vest on March 14, 2025.

Remarks:

Exhibit 24 - Power of Attorney. No securities are beneficially owned.